Laboratorios Farmaceuticos Rovi Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Juan Lopez-Belmonte Encina

İcra Kurulu Başkanı

€1.3m

Toplam tazminat

CEO maaş yüzdesi	55.2%
CEO görev süresi	17.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	5.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Juan Lopez-Belmonte Encina'un ücretlendirmesi Laboratorios Farmaceuticos Rovi'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	€165m
Jun 30 2024	n/a	n/a	€148m
Mar 31 2024	n/a	n/a	€138m
Dec 31 2023	€1m	€743k	€170m
Sep 30 2023	n/a	n/a	€197m
Jun 30 2023	n/a	n/a	€186m
Mar 31 2023	n/a	n/a	€194m
Dec 31 2022	€1m	€728k	€200m
Sep 30 2022	n/a	n/a	€176m
Jun 30 2022	n/a	n/a	€183m
Mar 31 2022	n/a	n/a	€182m
Dec 31 2021	€2m	€327k	€153m
Sep 30 2021	n/a	n/a	€113m
Jun 30 2021	n/a	n/a	€82m
Mar 31 2021	n/a	n/a	€71m
Dec 31 2020	€561k	€330k	€61m
Sep 30 2020	n/a	n/a	€55m
Jun 30 2020	n/a	n/a	€53m
Mar 31 2020	n/a	n/a	€46m
Dec 31 2019	€541k	€320k	€39m
Sep 30 2019	n/a	n/a	€33m
Jun 30 2019	n/a	n/a	€27m
Mar 31 2019	n/a	n/a	€18m
Dec 31 2018	€908k	€312k	€18m
Sep 30 2018	n/a	n/a	€16m
Jun 30 2018	n/a	n/a	€9m
Mar 31 2018	n/a	n/a	€18m
Dec 31 2017	€524k	€303k	€17m

Tazminat ve Piyasa: Juan 'nin toplam tazminatı ($USD 1.42M ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 2.70M ).

Tazminat ve Kazançlar: Juan 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Juan Lopez-Belmonte Encina

17.8yrs

Görev süresi

€1,346,000

Tazminat

Mr. Juan Lopez-Belmonte Encina has been Chief Executive Officer of Laboratorios Farmaceuticos ROVI, S.A. since October 2007 and served as its President from October 2020 to October 2022. He has been with L...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Juan Lopez-Belmonte Encina	Chairman & CEO	17.3yrs	€1.35m	Veri yok
Ivan Lopez-Belmonte Encina	Second Deputy Chairman & GM of Commercial and Development	17.3yrs	€552.00k	Veri yok
Javier Lopez-Belmonte Encina	First Deputy Chairman	17.3yrs	€554.00k	Veri yok
Marcos Pena Pinto	Independent Director	5.5yrs	€80.00k	Veri yok
Fatima Garcia	Independent Director	4.9yrs	€80.00k	Veri yok
Marina del Tellez	Director	2.5yrs	€80.00k	Veri yok
Teresa Santamaria	Independent Director	1.9yrs	€80.00k	Veri yok

5.5yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: 0ILL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).

Laboratorios Farmaceuticos Rovi Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Laboratorios Farmaceuticos Rovi, S.A., Annual General Meeting, Jun 24, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released

Investor sentiment deteriorates as stock falls 15%

Laboratorios Farmaceuticos Rovi, S.A. to Report Nine Months, 2024 Results on Nov 07, 2024

Second quarter 2024 earnings released

Upcoming dividend of €0.89 per share

Laboratorios Farmaceuticos Rovi, S.A. to Report First Half, 2024 Results on Jul 31, 2024

Laboratorios Farmaceuticos Rovi, S.A., Annual General Meeting, Jun 24, 2024

First quarter 2024 earnings released

Laboratorios Farmaceuticos Rovi, S.A. to Report Q1, 2024 Results on May 08, 2024

Less than half of directors are independent

Full year 2023 earnings released

Laboratorios Farmaceuticos Rovi, S.A. to Report Fiscal Year 2023 Results on Feb 27, 2024

Third quarter 2023 earnings released

Now 20% undervalued

Laboratorios Farmaceuticos Rovi, S.A. to Report Nine Months, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings released

Now 21% undervalued

Now 22% undervalued

Upcoming dividend of €1.05 per share at 3.1% yield

Now 20% undervalued

Full year 2022 earnings released: EPS: €3.73 (vs €2.76 in FY 2021)

Laboratorios Farmaceuticos Rovi, S.A. to Report Fiscal Year 2022 Final Results on Feb 28, 2023

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Laboratorios Farmaceuticos Rovi, S.A. to Report Q3, 2022 Results on Nov 03, 2022

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released

Now 30% undervalued after recent price drop

Laboratorios Farmaceuticos Rovi, S.A. to Report First Half, 2022 Results on Jul 27, 2022

Upcoming dividend of €0.77 per share

Less than half of directors are independent

Laboratorios Farmaceuticos Rovi, S.A. to Report Q1, 2022 Results on May 11, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released

Upcoming dividend of €0.31 per share

Laboratorios Farmaceuticos Rovi, S.A. announced that it expects to receive funding from Jefferies International Limited and another investor

First quarter 2021 earnings released: EPS €0.43

Revenue beats expectations

Full year 2020 earnings released: EPS €1.10 (vs €0.71 in FY 2019)

Laboratorios Farmaceuticos Rovi, S.A. to Report Fiscal Year 2020 Results on Feb 24, 2021

New 90-day high: €42.70

Market pulls back on stock over the past week

Market pulls back on stock over the past week

Upcoming Dividend of €0.14 Per Share

Third quarter 2020 earnings released: EPS €0.31

Laboratorios Farmaceuticos Rovi, S.A. to Report Nine Months, 2020 Results on Nov 05, 2020

Laboratorios Farmaceuticos Rovi, S.A. to Report First Half, 2020 Results on Jul 27, 2020

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi